JOURNAL - OFFICE OF LEGISLATIVE COUNSEL

• Document Type: CREST
• Collection: General CIA Records
• Document Number (FOIA) /ESDN (CREST): CIA-RDP78M02660R000300080044-0
• Release Decision: RIPPUB
• Original Classification: C
• Document Page Count: 2
• Document Creation Date: December 19, 2016
• Document Release Date: August 3, 2006
• Sequence Number: 44
• Publication Date: January 6, 1976
• Content Type: NOTES

Approved For Release 2006/08/09: CIA-RDP78MO266OR000300080044-0
Journal - Office of Legislative Counsel Page 2
Tuesday - 6 January 1976
5? LEGISLATION Called Geor
e Gilb
t
g
er
,
OMB, an uire w e er OMB needed a separate letter addressed to
them on the bills on congressional oversight before the Senate Government
Operations Committee. We have been asked for comments by both the
Committee and OMB. Gilbert said a letter to the Committee routed as
usual through OMB would be sufficient.
6. LIAISON Jane McMullan, on the staff
of the Senae ro iat C
r
pp p
ions onzmittee, called to request that someone
from the Agency come down and change the combinations on the Committee's
ments for two technicians to make the changes tomorrow afternoon.wyI then
advised Jane about our plans.
7. HEARING 'Met. with Jim Michie, Senate
Judiciary; u comma ee on ministrative Practice and.Procedure staff con-
cerning Senator Edward Kennedy'.s (D. ; Mass. ), informal. request that the
Agency reconsider the grounds for exempting certain portions of the 1963
IG report on drugs which was released under the Freedom of Information
Act. I informed Michie that except for the last sentence of paragraph 9 on
page 10, all of the claimed exemptions in the document were reconfirmed.
I left with Michie a revised page 10 which included the sentence previously
excluded. Michie asked that I meet with him. at'the earliest opportunity
to go over all of the Subcommittee's exhibits of Agency documents in their
report to be certain there are no problems.
MORKIDIF Page 1
 Approved For Releasu-2006i408/09 : CIA-RDP78MO266OR000300080044-0
relationship. The testing programs are conducted under accepted
scientific procedures including the use of control populations, the
employment of placebos, and the detailed observation, measurement,
recording, analysis, and publication of findings. Where health permits,
test subjects are voluntary participants in the program. _
9. A current development in the testing of new products is the
tightening of controls over dosages and procedures by the U. S. Food
and Drug Administration. Since MKULTRA files contained no docu-
mentation on this subject, it was not possible to appraise the signifi-
cance of this development for MKULTRA objectives. However,
interviews with the TSD officers concerned indicated that the new rules
are affecting procedures and causing controversy in research hospitals
and pharmaceutical houses. The TSD officers have close relationships
with key individuals in many of the leading U. S. pharmaceutical houses
and count on their continued close cooperation in obtaining materials
and services deemed vital to U. S. intelligence.
10. The final phase of testing of MKULTRA materials involves
their application to unwitting subjects in normal life settings. It was
noted earlier that the capabilities of MKULTRA substances to produce
disabling or discrediting effects or to i:icrease the effectiveness of
interrogation of hostile subjects cannot be established solely through
testing on volunteer populations. Reaction and attribution patterns are